Cargando…

Severe Acute Respiratory Syndrome (SARS)

Severe acute respiratory syndrome (SARS) is a new human disease caused by an animal coronavirus that adapted to efficient human-to-human transmission. The disease first emerged in November 2002 in Guangdong Province, China and spread globally within months. The SARS coronavirus (SARS CoV) affects mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Peiris, J.S.M., Poon, L.L.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149687/
http://dx.doi.org/10.1016/B978-012374410-4.00780-9
_version_ 1783520860507734016
author Peiris, J.S.M.
Poon, L.L.M.
author_facet Peiris, J.S.M.
Poon, L.L.M.
author_sort Peiris, J.S.M.
collection PubMed
description Severe acute respiratory syndrome (SARS) is a new human disease caused by an animal coronavirus that adapted to efficient human-to-human transmission. The disease first emerged in November 2002 in Guangdong Province, China and spread globally within months. The SARS coronavirus (SARS CoV) affects multiple organ systems with severe viral pneumonia as its main clinical manifestation but with diarrhea, lymphopenia, and mild liver dysfunction being common extra-pulmonary manifestations. Increasing age and the presence of underlying respiratory diseases worsens the prognosis. Unlike other respiratory viral infections, transmission of SARS was less frequent in the first 5 days of illness and correlated with low viral load in the upper respiratory tract at this stage of the illness. This fortuitous feature of the disease allowed the public health measures of case detection and patient isolation to interrupt virus transmission in the community and abort the SARS outbreak. Bats are a reservoir of a virus closely related to SARS CoV and this may be the likely precursor from which the human-adapted SARS CoV emerged. Small mammals such as ‘civet-cats’ (Paguma larvata) within live animal markets in southern China serve as amplifiers of infection and these markets were the likely interface where zoonotic transmission occurred. The viral spike protein is necessary and sufficient for inducing protective antibody responses and has been a key target in the development of candidate vaccines.
format Online
Article
Text
id pubmed-7149687
institution National Center for Biotechnology Information
language English
publishDate 2008
record_format MEDLINE/PubMed
spelling pubmed-71496872020-04-13 Severe Acute Respiratory Syndrome (SARS) Peiris, J.S.M. Poon, L.L.M. Encyclopedia of Virology Article Severe acute respiratory syndrome (SARS) is a new human disease caused by an animal coronavirus that adapted to efficient human-to-human transmission. The disease first emerged in November 2002 in Guangdong Province, China and spread globally within months. The SARS coronavirus (SARS CoV) affects multiple organ systems with severe viral pneumonia as its main clinical manifestation but with diarrhea, lymphopenia, and mild liver dysfunction being common extra-pulmonary manifestations. Increasing age and the presence of underlying respiratory diseases worsens the prognosis. Unlike other respiratory viral infections, transmission of SARS was less frequent in the first 5 days of illness and correlated with low viral load in the upper respiratory tract at this stage of the illness. This fortuitous feature of the disease allowed the public health measures of case detection and patient isolation to interrupt virus transmission in the community and abort the SARS outbreak. Bats are a reservoir of a virus closely related to SARS CoV and this may be the likely precursor from which the human-adapted SARS CoV emerged. Small mammals such as ‘civet-cats’ (Paguma larvata) within live animal markets in southern China serve as amplifiers of infection and these markets were the likely interface where zoonotic transmission occurred. The viral spike protein is necessary and sufficient for inducing protective antibody responses and has been a key target in the development of candidate vaccines. 2008 2008-07-30 /pmc/articles/PMC7149687/ http://dx.doi.org/10.1016/B978-012374410-4.00780-9 Text en Copyright © 2008 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Peiris, J.S.M.
Poon, L.L.M.
Severe Acute Respiratory Syndrome (SARS)
title Severe Acute Respiratory Syndrome (SARS)
title_full Severe Acute Respiratory Syndrome (SARS)
title_fullStr Severe Acute Respiratory Syndrome (SARS)
title_full_unstemmed Severe Acute Respiratory Syndrome (SARS)
title_short Severe Acute Respiratory Syndrome (SARS)
title_sort severe acute respiratory syndrome (sars)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149687/
http://dx.doi.org/10.1016/B978-012374410-4.00780-9
work_keys_str_mv AT peirisjsm severeacuterespiratorysyndromesars
AT poonllm severeacuterespiratorysyndromesars